RxDoctor Payments Data

Graham Farnham

Psychiatric/Mental Health · Beacon, NYNPI 1659822278

Payments from drug & device makers

$2,672in general payments, 2019–2025

Across 155 payments — averaging $17.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$928
  • Otsuka America Pharmaceutical, Inc.$649
  • Teva Pharmaceuticals USA, Inc.$271
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$233
  • Supernus Pharmaceuticals, Inc.$184
  • Takeda Pharmaceuticals U.S.A., Inc.$140
  • plus $267 from 5 others

What the payments were for

  • Food & beverage$2,672100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,672 in reported general payments places this provider in the 80th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$16,570
Medicare patients
32
Services billed
193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl19$44,071
RexultiBrexpiprazole21$33,094
Pregabalin18$7,554
Ambien CrZolpidem Tartrate11$6,817
TrintellixVortioxetine Hydrobromide13$5,913
Quetiapine Fumarate53$1,633
Aripiprazole59$1,437
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine23$1,279
Clonazepam153$1,272
Venlafaxine Hcl ErVenlafaxine Hcl34$1,160
Duloxetine Hcl11$1,018
Trazodone Hcl92$798
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine31$710
Mirtazapine46$700
Fluvoxamine Maleate29$584

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$928$44,07119 claims
Otsuka America Pharmaceutical, Inc.Rexulti$649$33,09421 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$140$5,91313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Beacon

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →